Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026)

Sunshine Biopharma has reported Return on Capital Employed for 11 years, with the latest figure at 27.36% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 368.0% year-over-year to 27.36%; the trailing twelve-month figure through Mar 2026 stood at 27.36% (down 368.0% YoY), and the FY2025 full-year result was 26.08%, down 41.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 27.36%, down from 25.58% in the prior quarter.
• The five-year high for Return on Capital Employed was 9.57% in Q3 2022, with the low at 130.15% in Q1 2023.
• Historically, Return on Capital Employed has averaged 43.88% across 5 years, with a median of 25.58% in 2025.
• Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 27810 bps — and 2023, when it plunged 11143 bps.
• Sunshine Biopharma's Return on Capital Employed stood at 96.01% in 2022, then surged by 77 bps to 21.91% in 2023, then retreated by 10 bps to 24.02% in 2024, then slipped by 7 bps to 25.58% in 2025, then dropped by 7 bps to 27.36% in 2026.
• The last three Return on Capital Employed figures came in at 27.36% (Q1 2026), 25.58% (Q4 2025), and 25.82% (Q3 2025), per Business Quant data.